Incyte Corporation INCY
120.30 USD -1.59 (-1.30%)
At closeNov 10, 2026, 4:21 PM EST
120.30 0.00 0.00%
After hours · Nov 10, 4:21 PM ET
119.03 Day range 121.25
89.25 52-week range 132.60
- YTD
- +21.80%
- 1 year
- +13.51%
News
benzinga.com Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer Trial designed to improve outcomes through Signatera™-guided Treatment on MRD (TOMR), identifying high-risk patients for curative-intent treatmentNatera, Inc. (NASDAQ:NTRA), a global leader in…
businesswire.com 2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the…
benzinga.com Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150 Leerink Partners analyst Andrew Berens maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $154 to $150.
benzinga.com $1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 17.11%. Currently, Incyte has a market capitalization of…
defenseworld.net Incyte Corporation $INCY Shares Newly Purchased by Compass Financial Management LLC Compass Financial Management LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) in the third quarter, according to the company in its most recent Form 13F filing with the…
benzinga.com Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology…
defenseworld.net Aware Super Pty Ltd as trustee of Aware Super Sells 13,693 Shares of Incyte Corporation $INCY Aware Super Pty Ltd as trustee of Aware Super lowered its position in Incyte Corporation (NASDAQ: INCY) by 4.5% during the undefined quarter, according to the company in its most recent Form 13F…
benzinga.com Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108 Bernstein analyst Jeffrey Walch maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $104 to $108.
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.- benzinga.com Barclays Maintains Overweight on Incyte, Raises Price Target to $143 Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.- benzinga.com Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127 Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
247wallst.com Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.- benzinga.com Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144 Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
seekingalpha.com Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net…
zacks.com INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
seekingalpha.com Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
marketbeat.com What Incyte (INCY) Said on Its Q3 Earnings Call Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in…
zacks.com Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
zacks.com Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
benzinga.com Incyte Q3 2026 Earnings Call Transcript Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $5.130 billion-$5.260 billion to $5.210 billion-$5.300 billion vs $5.929 billion estimate.- benzinga.com Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate Incyte (NASDAQ:INCY) reported quarterly losses of $(3.60) per share which beat the analyst consensus estimate of $(3.85) by 6.49 percent. This is a 259.29 percent decrease over earnings of $2.26 per…
businesswire.com Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
seekingalpha.com Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
marketbeat.com Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,”…
zacks.com Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
benzinga.com Genmab's Encouraging Oncology Data Boosts Investor Optimism Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.
businesswire.com Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
gurufocus.com Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer [url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's
businesswire.com Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's…
businesswire.com Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.- benzinga.com TD Cowen Maintains Buy on Incyte, Raises Price Target to $140 TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.
benzinga.com Why Is Arcutis Biotherapeutics Stock Surging Thursday? Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.- benzinga.com Truist Securities Maintains Hold on Incyte, Raises Price Target to $115 Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.
- benzinga.com RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114 RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.
benzinga.com If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of…- benzinga.com Stifel Maintains Buy on Incyte, Raises Price Target to $157 Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.
benzinga.com If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of…
benzinga.com Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128 Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.- benzinga.com JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123 JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
benzinga.com FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
benzinga.com Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.- benzinga.com HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.
- benzinga.com RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.
- benzinga.com Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3 Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic…